# Pemetrexed

## Alimta inj 100mg

##### 臨採

| TAH Drug Code      | [IALI1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IALI1)                                                                                                                                                                                                                                                                         |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | In combination with cisplatin for the treatment of malignant pleural mesothelioma. Monotherapy for the 2nd-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. In combination with cisplatin therapy for the 1st-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. |
| Dosing             | 500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Severe hypersensitivity to pemetrexed or any component of the formulation. Canadian labeling: Additional contraindications (not in the US labeling): Concomitant yellow fever vaccine.                                                                                                                                                         |
| Adverse Effects    | Bone marrow depression with neutropenia, leukopenia, anemia & thrombocytopenia; fatigue; fever; GI toxicity with nausea & vomiting, constipation, anorexia, anorexia, stomatitis/pharyngitis, diarrhea; dyspnea; chest pain; infection; rash/desquamation.                                                                                     |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                |
| Lactation          | Hold Breast Feeding                                                                                                                                                                                                                                                                                                                            |

## ALIMTA inj 500mg

##### 臨採

| TAH Drug Code      | [IALI5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IALI5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | In combination with cisplatin for the treatment of malignant pleural mesothelioma. Monotherapy for the 2nd-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. In combination with cisplatin therapy for the 1st-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer.                                                                                                                                                                                                                                                                                                                                                   |
| Dosing             | 500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Severe hypersensitivity to pemetrexed or any component of the formulation. Canadian labeling: Additional contraindications (not in the US labeling): Concomitant yellow fever vaccine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Bone marrow depression with neutropenia, leukopenia, anemia & thrombocytopenia; fatigue; fever; GI toxicity with nausea & vomiting, constipation, anorexia, anorexia, stomatitis/pharyngitis, diarrhea; dyspnea; chest pain; infection; rash/desquamation. Dermatologic: Itching, Itching (1% to 7% ), Peeling of skin Gastrointestinal: Constipation (1% to 21% ), Diarrhea (5% to 17% ), Loss of appetite (19% to 27% ), Nausea (19% to 82% ), Pharyngitis, Stomatitis, Vomiting (9% to 57% ) Hematologic: Anemia, All Grades (15% to 33% ), Leukopenia, All Grades (6% to 53% ), Neutropenia, All Grades (6% to 56% ), Thrombocytopenia, All Grades (1% to 23% ) Other: Fatigue (25% to 48% ) |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | Hold Breast Feeding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

